Subtopic Deep Dive
HLA-B*5701 Screening for Abacavir Hypersensitivity
Research Guide
What is HLA-B*5701 Screening for Abacavir Hypersensitivity?
HLA-B*5701 screening identifies carriers of the HLA-B*5701 allele in HIV patients prior to abacavir therapy to prevent severe T-cell mediated hypersensitivity reactions.
The HLA-B*5701 allele strongly associates with abacavir-induced delayed hypersensitivity reactions occurring >6 hours post-administration (Li et al., 2021; 24 citations). Routine genotyping has reduced hypersensitivity incidence substantially (MacArthur, 2010; 16 citations). Validation of real-time PCR methods supports clinical implementation (Jung et al., 2017; 10 citations).
Why It Matters
HLA-B*5701 screening prevents life-threatening abacavir hypersensitivity in HIV treatment, reducing incidence through pre-treatment genotyping as shown in clinical reviews (MacArthur, 2010). Cost-effective protocols integrate into guidelines, minimizing adverse events like liver toxicity (Di Filippo et al., 2014; 11 citations). Genomic risk factor studies enable personalized pharmacotherapy, lowering mortality from delayed drug hypersensitivity reactions (Li et al., 2021).
Key Research Challenges
Genotyping Assay Optimization
Developing accurate real-time PCR for HLA-B*5701 detection requires optimized hydrolysis probes to minimize false negatives in diverse populations (Jung et al., 2017; 10 citations). Validation across ethnic groups remains incomplete. Clinical labs face standardization issues for high-throughput screening.
Cost-Effectiveness in Low-Resource Settings
Implementing routine screening in resource-limited HIV programs balances costs against hypersensitivity prevention benefits (MacArthur, 2010; 16 citations). Pediatric use without testing raises safety concerns (Musiime and Prendergast, 2015; 1 citation). Economic models need refinement for global guidelines.
Distinguishing Hypersensitivity Phenotypes
Differentiating abacavir hypersensitivity from liver toxicity or co-infection effects complicates diagnosis (Di Filippo et al., 2014; 11 citations). Viral polymorphisms do not reliably predict HLA-B*5701 status (Waters et al., 2007; 8 citations). Mechanistic studies link allele to T-cell responses (Li et al., 2021).
Essential Papers
Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions
Yueran Li, Pooja Deshpande, Rebecca J. Hertzman et al. · 2021 · Frontiers in Genetics · 24 citations
Adverse drug reactions (ADRs) remain associated with significant mortality. Delayed hypersensitivity reactions (DHRs) that occur greater than 6 h following drug administration are T-cell mediated w...
Abacavir/lamivudine combination in the treatment of HIV: a review
Rodger D. MacArthur · 2010 · Therapeutics and Clinical Risk Management · 16 citations
Abacavir has been at the center of research and clinical interest in the last two years. The frequency of the associated abacavir hypersensitivity syndrome has decreased substantially since the int...
Abacavir-induced liver toxicity in an HIV-infected patient
Elisa Di Filippo, Diego Ripamonti, Marco Rizzi · 2014 · AIDS · 11 citations
Antiretroviral drug-related liver toxicity is one of the main causes of treatment discontinuation in HIV-infected patients [1] occurring in 2–14%, with a higher risk in the presence of viral hepati...
Development of HLA-B*57:01 Genotyping Real-Time PCR with Optimized Hydrolysis Probe Design
Hou-Sung Jung, Gregory J. Tsongalis, Joel A. Lefferts · 2017 · Journal of Molecular Diagnostics · 10 citations
Polymorphisms at Position 245 of HIV Reverse Transcriptase Do Not Accurately Predict the Presence of Human Leukocyte Antigen B*5701
Laura Waters, N Mackie, A. Pozniak et al. · 2007 · Clinical Infectious Diseases · 8 citations
mococcal isolates from patients with IPD were sent to the National Microbiology Center for serotyping.In the 2000-2002 seasons, when PCV7 was initially not available, and later, when it we availabl...
Abacavir-induced fulminant hepatic failure in a HIV/HCV co-infected patient
Christopher Haas, Mary Rodriguez Ziccardi, Jody Borgman · 2015 · BMJ Case Reports · 6 citations
Abacavir hypersensitivity is a rare, yet significant adverse reaction that results in a spectrum of physical and laboratory abnormalities, and has been postulated to stem from a variety of aetiolog...
ABACAVIR LOADED NANOPARTICLES: PREPARATION, PHYSICOCHEMICAL CHARACTERIZATION AND IN VITRO EVALUATION
Felix Sunday Yusuf · 2016 · Universal Journal of Pharmaceutical Research · 4 citations
Objectives: Abacavir is a nucleoside analog reverse transcriptase inhibitor (NRTI), antiretroviral drug; it is used in treatment of AIDS. The present study deals with the formulation and evaluation...
Reading Guide
Foundational Papers
Start with MacArthur (2010; 16 citations) for screening history and impact; Waters et al. (2007; 8 citations) on prediction limits; Di Filippo (2014; 11 citations) for toxicity cases.
Recent Advances
Li et al. (2021; 24 citations) for genomic mechanisms; Jung et al. (2017; 10 citations) for genotyping advances; Musiime (2015; 1 citation) on pediatric challenges.
Core Methods
Real-time PCR genotyping (Jung et al., 2017); T-cell mediated DHR analysis (Li et al., 2021); clinical incidence tracking (MacArthur, 2010).
How PapersFlow Helps You Research HLA-B*5701 Screening for Abacavir Hypersensitivity
Discover & Search
Research Agent uses searchPapers and exaSearch to find HLA-B*5701 papers like 'Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions' by Li et al. (2021), then citationGraph reveals connections to MacArthur (2010) review on screening impact.
Analyze & Verify
Analysis Agent applies readPaperContent to extract genotyping protocols from Jung et al. (2017), verifies claims with verifyResponse (CoVe), and runs PythonAnalysis on incidence data from Li et al. (2021) for GRADE evidence grading on screening efficacy.
Synthesize & Write
Synthesis Agent detects gaps in pediatric screening from Musiime (2015), flags contradictions between toxicity cases (Di Filippo, 2014), while Writing Agent uses latexEditText, latexSyncCitations for MacArthur (2010), and latexCompile for guideline drafts with exportMermaid for risk flowcharts.
Use Cases
"Extract HLA-B*5701 allele frequencies and run statistical analysis from abacavir papers."
Research Agent → searchPapers → Analysis Agent → readPaperContent (Li et al., 2021) → runPythonAnalysis (pandas frequency stats, matplotlib plots) → CSV export of incidence rates.
"Draft LaTeX review on HLA-B*5701 screening guidelines with citations."
Synthesis Agent → gap detection → Writing Agent → latexEditText (intro section) → latexSyncCitations (MacArthur 2010, Jung 2017) → latexCompile → PDF with embedded citations.
"Find code for HLA genotyping analysis from related repos."
Research Agent → searchPapers (Jung 2017) → Code Discovery → paperExtractUrls → paperFindGithubRepo → githubRepoInspect → Python scripts for PCR probe design.
Automated Workflows
Deep Research workflow conducts systematic review: searchPapers (50+ abacavir papers) → citationGraph → DeepScan (7-step verification with CoVe on Li et al., 2021 claims). Theorizer generates hypotheses on allele mechanisms from MacArthur (2010) and Jung (2017), outputting Mermaid diagrams of screening pathways.
Frequently Asked Questions
What is HLA-B*5701 screening?
HLA-B*5701 screening tests HIV patients for the allele before abacavir to prevent hypersensitivity (MacArthur, 2010).
What methods detect HLA-B*5701?
Real-time PCR with optimized hydrolysis probes validates genotyping (Jung et al., 2017; 10 citations).
What are key papers?
Li et al. (2021; 24 citations) on genomic risks; MacArthur (2010; 16 citations) on screening impact.
What open problems exist?
Pediatric safety without testing (Musiime, 2015); cost in low-resource areas; phenotype differentiation (Di Filippo, 2014).
Research Drug-Induced Adverse Reactions with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching HLA-B*5701 Screening for Abacavir Hypersensitivity with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers
Part of the Drug-Induced Adverse Reactions Research Guide